瓦桑特·纳拉辛汉 Vasant Narasimhan — 纽约达士 CEO
FORTUNE 500 #287

瓦桑特·纳拉辛汉

Vasant Narasimhan

纽约达士 (Novartis)

领导Switzerland大型Pharmaceuticals企业运营

广告

专业领域

医疗健康管理 生命科学

Healthcare management, life sciences

核心贡献

领导Switzerland大型Pharmaceuticals企业运营

Leading large-scale Pharmaceuticals operations in Switzerland

最新观点

  • Novartis(官方新闻稿) · 2026-10-27 阅读原文

    诺华CEO万思瀚评2026年三季度业绩:“诺华第三季度实现了稳健的销售增长,重点品牌和上市新品超过了仿制药侵蚀的影响,体现了业务的替代增长力。叠加生产力提升举措,这带来了强劲的盈利表现,并使我们得以上调全年指引。与此同时,我们持续推进研发管线:remibrutinib 在复发型多发性硬化症的III期结果积极,Rhapsido 与 Pluvicto 在美国获得适应症扩展,pelabresib 在欧盟完成首次申报。”当季净销售额145亿美元(按固定汇率+4%),核心营业利润+10%,核心营业利润率41.6%(+2个百分点),核心每股收益2.46美元。

    "Novartis delivered solid sales growth in Q3, as priority brands and launches more than offset generic erosion, demonstrating the replacement power of the business. Combined with productivity efforts, this drove strong bottom-line performance and allowed us to upgrade our full-year guidance. At the same time, we continued to advance our pipeline, with positive Phase III results for remibrutinib in RMS, label expansions for Rhapsido and Pluvicto in the US, and the first submission for pelabresib in the EU." - Vas Narasimhan, CEO of Novartis. Q3 net sales were USD 14.5 billion (+4% cc), core operating income rose 10% cc at a 41.6% core margin (+2 pts cc), and core EPS was USD 2.46 (+8% cc).

  • Novartis(官方新闻稿) · 2026-10-27 阅读原文

    诺华CEO万思瀚评2026年三季度业绩:“诺华第三季度实现了稳健的销售增长,重点品牌和上市新品超过了仿制药侵蚀的影响,体现了业务的替代增长力。叠加生产力提升举措,这带来了强劲的盈利表现,并使我们得以上调全年指引。与此同时,我们持续推进研发管线:remibrutinib 在复发型多发性硬化症的III期结果积极,Rhapsido 与 Pluvicto 在美国获得适应症扩展,pelabresib 在欧盟完成首次申报。”当季净销售额145亿美元(按固定汇率+4%),核心营业利润+10%,核心营业利润率41.6%(+2个百分点),核心每股收益2.46美元。

    "Novartis delivered solid sales growth in Q3, as priority brands and launches more than offset generic erosion, demonstrating the replacement power of the business. Combined with productivity efforts, this drove strong bottom-line performance and allowed us to upgrade our full-year guidance. At the same time, we continued to advance our pipeline, with positive Phase III results for remibrutinib in RMS, label expansions for Rhapsido and Pluvicto in the US, and the first submission for pelabresib in the EU." - Vas Narasimhan, CEO of Novartis. Q3 net sales were USD 14.5 billion (+4% cc), core operating income rose 10% cc at a 41.6% core margin (+2 pts cc), and core EPS was USD 2.46 (+8% cc).

广告